{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:00:44Z","timestamp":1780977644492,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107213","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:52:50Z","timestamp":1777333970000},"page":"107213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Assessment of serum FAM19A5 level in patients with Neuromyelitis Optica spectrum disorder"],"prefix":"10.1016","volume":"111","author":[{"given":"Hamdy Naguib","family":"El-Tellawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ahmed","family":"Abd-Elhameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa Ahmed","family":"Elzohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek Ali","family":"Rageh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Khairy","family":"Danial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa Mokhtar","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin Mohieldin","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107213_bib0001","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","article-title":"Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis","volume":"271","author":"Arnett","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107213_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2026.107213_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103761","article-title":"Differences in clinical phenotype, laboratory, and imaging manifestations between AQP4 IgG positive and AQP4 MOG IgG double negative NMOSD: how to correctly diagnose the two","volume":"24","author":"Chu","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2026.107213_bib0004","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbi.2020.03.021","article-title":"Serum FAM19A5 levels: a novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder","volume":"87","author":"Han","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.msard.2026.107213_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.msard.2026.107213_bib0006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5603\/PJNNS.a2022.0046","article-title":"Update on pathology of central nervous system inflammatory demyelinating diseases","volume":"56","author":"Kalinowska-\u0141yszczarz","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"issue":"13","key":"10.1016\/j.msard.2026.107213_bib0007","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1177\/1352458519885489","article-title":"Serum FAM19A5 in neuromyelitis optica spectrum disorders: can it be a new biomarker representing clinical status?","volume":"26","author":"Lee","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107213_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8895900","article-title":"Association of serum FAM19A5 with cognitive impairment in vascular dementia","volume":"2020","author":"Li","year":"2020","journal-title":"Dis. Markers"},{"key":"10.1016\/j.msard.2026.107213_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.795539","article-title":"Development and validation of a plasma FAM19A5 and MRI-based radiomics model for prediction of Parkinson\u2019s disease and Parkinson\u2019s disease with depression","volume":"15","author":"Li","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.msard.2026.107213_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120298","article-title":"Repeated lumbar puncture in search of oligoclonal bands \u2013 What is the yield?","volume":"439","author":"Mermelstein","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.107213_bib0011","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jalz.2016.09.002","article-title":"Two novel loci, COBL and SLC10A2, for Alzheimer\u2019s disease in African Americans","volume":"13","author":"Mez","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.msard.2026.107213_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.811351","article-title":"Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands","volume":"12","author":"Probert","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2026.107213_bib0013","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acschemneuro.0c00757","article-title":"FAM19A (TAFA): an emerging family of neurokines with diverse functions in the central and peripheral nervous system","volume":"12","author":"Sarver","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.msard.2026.107213_bib0014","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fnins.2019.00917","article-title":"FAM19A5 expression during embryogenesis and in the adult traumatic brain of FAM19A5-LacZ knock-in mice","volume":"13","author":"Shahapal","year":"2019","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2026.107213_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","article-title":"Outcome measures in clinical trials for multiple sclerosis","volume":"31","author":"Van Munster","year":"2017","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.msard.2026.107213_bib0016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600249X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600249X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:36:21Z","timestamp":1780976181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600249X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":16,"alternative-id":["S221103482600249X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107213","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of serum FAM19A5 level in patients with Neuromyelitis Optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107213"}}